A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Condition(s) studied
Investigational drug(s) / intervention(s)
GSK5764227: Participants will receive GSK5764227.
Bevacizumab: Participants will receive bevacizumab.
Fluorouracil: Participants will receive fluorouracil.
leucovorin: Participants will receive leucovorin.
Enzalutamide: Participants will receive enzalutamide.
Study summary
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.
Eligibility
Primary outcome measure(s)
- Number of participants with adverse events (AEs), Serious AEs (SAEs), AE of special interest (AESIs) and AEs leading to dose modifications — Up to approximately 31 weeks
- Number of participants with AEs, SAEs, AESIs, and AEs leading to dose modifications by severity — Up to approximately 31 weeks
- Number of participants with dose limiting toxicities (DLTs) — Up to approximately 31 weeks
- Number of participants with clinically significant changes in Vital Signs, Body Weight, Laboratory Tests [Hematology, Clinical Chemistry, Urinalysis], Cardiac Function [ECG], and Eastern Cooperative Oncology Group (ECOG) performance status — Up to approximately 31 weeks
Trial sites (22)
| Facility | City | Region | Status |
|---|---|---|---|
| GSK Investigational Site | Reunion | Florida | Recruiting |
| GSK Investigational Site | New Hyde Park | New York | Recruiting |
| GSK Investigational Site | Philadelphia | Pennsylvania | Recruiting |
| GSK Investigational Site | Nashville | Tennessee | Recruiting |
| GSK Investigational Site | Dallas | Texas | Recruiting |
| GSK Investigational Site | Douglas | Queensland | Recruiting |
| GSK Investigational Site | Tugun | Queensland | Recruiting |
| GSK Investigational Site | Geelong | Victoria | Recruiting |
| GSK Investigational Site | Bendigo | Australia | Recruiting |
| GSK Investigational Site | Ottawa | Ontario | Recruiting |
| GSK Investigational Site | Toronto | Ontario | Recruiting |
| GSK Investigational Site | Seoul | South Korea | Recruiting |
| GSK Investigational Site | Seoul | South Korea | Recruiting |
| GSK Investigational Site | Seoul | South Korea | Recruiting |
| GSK Investigational Site | Barcelona | Spain | Recruiting |
| GSK Investigational Site | Madrid | Spain | Recruiting |
| GSK Investigational Site | Madrid | Spain | Recruiting |
| GSK Investigational Site | Madrid | Spain | Recruiting |
| GSK Investigational Site | Málaga | Spain | Recruiting |
| GSK Investigational Site | Leicester | United Kingdom | Recruiting |
| GSK Investigational Site | London | United Kingdom | Recruiting |
| GSK Investigational Site | Sutton | United Kingdom | Recruiting |
More GlaxoSmithKline trials in the UK
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07277270 on ClinicalTrials.gov ↗ ← All trials in the UK